Company intelligence / Profile preview
Ascle Therapeutics
Suzhou, Jiangsu, Chinaascletx.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ascle Therapeutics develops NK and CAR-NK cell therapies, with its most advanced program ASC-101 targeting ROBO1 in breast and other cancers at IND application stage in China, and additional ROBO1-targeted and gene-edited NK programs in preclinical or discovery stages.[3]
- Therapeutic areas
- OncologyNeurologyDermatology
- Modalities
- Cell therapyNK cell therapyCAR-NK cell therapyGene editing
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Porton Advanced Solutions (Porton Advanced) – strategic partnership to promote application of NK cells in cancer prevention, beauty, and anti-aging, including development and manufacturing support for NK and CAR-NK products.[1][5]
Beyond the preview
Go deeper on Ascle Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ascle Therapeutics.